Iovance Biotherapeutics, Inc.IOVANASDAQ
Loading
Operating cash flow minus capital expenditures
Latest
$-336.24M
↓ 46% vs avg
Percentile
P14
Within normal range
Streak
2 yr
Consecutive growthContracting
Average
$-229.72M
Historical baseline
| Period | Value | YoY Change |
|---|---|---|
| TTM | $-336.24M | +7.6% |
| 2024 | $-364.05M | +5.2% |
| 2023 | $-384.11M | -22.6% |
| 2022 | $-313.18M | -18.0% |
| 2021 | $-265.51M | -5.4% |
| 2020 | $-251.93M | -51.9% |
| 2019 | $-165.81M | -61.8% |
| 2018 | $-102.45M | -28.5% |
| 2017 | $-79.74M | -133.2% |
| 2016 | $-34.19M | - |